Physician profile
Anna Adekugbe
NPI 1982999751
$348.22
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $40.30 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $121.86 | 2024 | |
| Neos Therapeutics, LP | $28.99 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $28.74 | 2019-2020 | |
| Pfizer INC. | $28.63 | 2019-2020 | |
| Tris Pharma INC | $28.25 | 2019 | |
| Cranial Technologies, INC | $25.40 | 2019 | |
| Sobi, INC | $21.78 | 2019 | |
| Mylan Specialty L.P. | $19.26 | 2019 | |
| Circassia INC. | $17.03 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.46 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Adekugbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.